decreased breath sounds over lung bases, a systolic murmur over the apex, and significant contractures on elbows and knees. She was coherent, oriented to all spheres, with intact cranial nerves, but with impaired recall. Upper extremity muscle testing was 4/5, while that of the lower extremities were 3/5. There was severe muscle atrophy, no fasciculations or other involuntary movements, no sensory deficits, no abnormal reflexes, and no signs of meningeal irritation. No oral ulcers, joint swelling, nor rash was noted. Work up showed anaemia, leukopenia, positive ANA, and positive anti-dsDNA. Serum electrolytes and urinalysis were normal. Chest radiograph showed interstitial infiltrates, while Mantoux test was negative. Cranial magnetic resonance imaging with contrast showed abnormal white matter intensities at the frontoparietal, periventricular, and subcortical regions, communicating hydrocephalus, and cortical cerebral and cerebellar atrophy. Cerebrospinal fluid analysis was normal. She showed remarkable improvement with intravenous antibiotics and corticosteroids. Upon discharge, she had good well-being, appetite, cognition, and mood, and was already able to ambulate with assistance. She received cyclophosphamide pulse therapy and underwent physical rehabilitation.

Conclusions Normal-pressure hydrocephalus may be part of the presenting manifestations of paediatric SLE.

131 OUTCOME OF FILIPINO CHILDREN WITH LUPUS NEPHRITIS TREATED WITH A MODIFIED TREATMENT REGIMEN USING CYCLOPHOSPHAMIDE

MT Collante*, C Bernal. *University of Santo Tomas Hospital, Department of Pediatrics-Section of Paediatric Rheumatology, Manila, Philippines*

10.1136/lupus-2017-000215.131

Background and Aims The current therapeutic strategy for childhood-onset lupus nephritis (LN) involves an induction phase, aiming to promote remission, and a maintenance phase control disease and prevent relapses. Various regimens have been used worldwide, which differ in drug of choice and dosage, and duration of the induction and maintenance phases. This study evaluated treatment outcome and adverse event occurrence in Filipinos with childhood-onset LN.

Methods Medical records of patients diagnosed with childhood-onset LN who received an extended induction phase of 9 months followed by a maintenance phase of 5 quarterly intravenous cyclophosphamide pulses from year 2006 to 2014 at the University of Santo Tomas Hospital were reviewed.

Results Nineteen patients completed the modified regimen (94.7% female, mean age 11.2±3.7 years at lupus diagnosis, mean LN duration to completion of treatment 30.6±5.2 months). At 9 months, 47.4% (9/19) reached complete remission, and 52.6% (10/19) were in partial remission. After 9 monthly and 5 quarterly pulses, 94.7% (18/19) was with complete treatment response. One patient relapsed during the maintenance phase and was with partial response at the end of treatment. The random urine protein:creatinine ratio and disease activity were significantly improved in all 19 patients. Treatment failure was not noted in any of the patients at the end of maintenance phase and at completion. Reported adverse events were gastrointestinal symptoms (100%), mild infections (94.7%), alopecia (89.5%), severe infections (10.5%), menstrual irregularities (33.3%), and hematologic disturbances (26.3%).

Conclusions A modified regimen of 9 monthly and 5 quarterly cyclophosphamide pulses may be an effective therapeutic option for childhood-onset LN.

132 SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODIES IN A CHILD WITH NOONAN SYNDROME

¹A Gupta*, ¹A Kumar, ²N Todurkar, ¹D Suri, ³I Panigrahi, ⁴J Ahluwalia, ¹S Singh. ¹PGIMER, Allergy Immunology Unit- Advanced Paediatrics Centre, Chandigarh, India; ²PGIMER, Advanced Paediatrics Centre, Chandigarh, India; ³PGIMER, Genetics and Metabolic Unit- Advanced Paediatrics Centre, Chandigarh, India; ⁴PGIMER, Department of Haematology, Chandigarh, India

10.1136/lupus-2017-000215.132

Background and Aims Autoimmune dysfunction has been described in patients with Noonan Syndrome (NS). Till date, 9 patients with systemic lupus erythematosus (SLE) and NS have been reported. However, exact relationship between SLE and NS is not known.

Methods To describe the clinical presentation of a child with SLE and NS.

Results A 10-years-old boy presented with fever, gradually progressive dyspnoea, pain in bilateral elbow and knee joints for 8 months. His past and family history was normal. Weight and height were <-3 z-score for his age. He had a long face with relatively large ears, down slanting palpebral fissure and livedo reticularis over lower limbs. Grade III ejection systolic murmur was present at pulmonary area along with loud second heart sound. He had hypertonia with brisk deep tendon reflexes in bilateral lower limbs, bilateral ankle clonus and extensor plantar response.

Investigations revealed anaemia, thrombocytopenia, leucopenia, elevated acute phase reactants and aPTT prolongation. His antinuclear antibody was positive by indirect immunofluorescence (4+ homogenous), anti-double stranded deoxyribonucleic acid was elevated and direct coomb test and lupus anticoagulant were positive along with low serum complement 3 level. Echocardiography revealed mitral valve prolapse and mitral regurgitation. Magnetic resonance imaging of brain revealed chronic lacunar infarct in medial aspect of right thalamus.

A diagnosis of SLE, APLA and NS was made and treatment with oral prednisolone, hydroxychloroquine, acetyl salicylate and low molecular weight heparin was initiated.

Conclusions Autoimmune conditions including SLE are being increasingly described in patients with NS requiring close monitoring and long term follow up.

133 SOLUBLE CXCL16 IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS

A Hassan. *Tanta, Egypt*

10.1136/lupus-2017-000215.133

Background and Aims Systemic lupus erythematosus (SLE) is characterised by autoantibodies directed against self antigens, leading to inflammatory damage of many target organs. The inflammatory soluble chemokine CXC motif ligand 16 (sCXCL16) has been proposed as an important pathogenic mediator in inflammatory diseases, such as juvenile SLE.